(Q44790776)

6 December 2017

title

Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification (English)

1 reference

6 December 2017

0 references

0 references

1 reference

Diana Hernández-Flórez

object named as

Diana Hernández-Flórez

4

0 references

author name string

Inmaculada de la Torre

1

1 reference

6 December 2017

Lara Valor

2

1 reference

6 December 2017

Juan Carlos Nieto

3

1 reference

6 December 2017

Lina Martinez

5

1 reference

6 December 2017

Carlos M Gonzalez

6

1 reference

6 December 2017

Indalecio Monteagudo

7

1 reference

6 December 2017

Javier Lopez Longo

8

1 reference

6 December 2017

Maria Montoro

9

1 reference

6 December 2017

Luis Carreño

10

1 reference

6 December 2017

publication date

1 June 2013

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

6 December 2017

published in

1 reference

6 December 2017

volume

13

1 reference

6 December 2017

issue

3

1 reference

6 December 2017

page(s)

407-414

1 reference

Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature

6 December 2017

cites work

1 reference

Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease.

21 January 2018

1 reference

Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings

21 January 2018

1 reference

Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.

21 January 2018

1 reference

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).

21 January 2018

1 reference

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

21 January 2018

1 reference

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

Economic consequences of established rheumatoid arthritis and its treatment

21 January 2018

1 reference

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population

21 January 2018

1 reference

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

21 January 2018

1 reference

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

21 January 2018

1 reference

Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review

21 January 2018

1 reference

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

21 January 2018

1 reference

Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.

21 January 2018

1 reference

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

21 January 2018

1 reference

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERP.13.24

1 reference

6 December 2017

1 reference